Drugs / HER2 - primed Dendritic cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05504707 | Aug 2022 → Oct 2026 expected | triple-negative breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER2 - primed Dendritic cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05504707 ↗ |
| Modality | Vaccine | “investigational vaccine called Dendritic Cell (DC) vaccine” NCT05504707 ↗ |
| Route | Other | “8 intratumoral injections” NCT05504707 ↗ |